Frag 176-191

Frag 176-191 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). It has been studied in preclinical models for its ability to modulate fat metabolism without the insulin or IGF-1 signaling typically associated with full-length hGH. It is not considered anabolic but is of interest for its targeted lipolytic properties in laboratory research.

• Derived from the C-terminal region (176-191) of human growth hormone (hGH)
• Activates GH receptor-related fat-burning pathways without affecting IGF-1 or glucose metabolism
• Stimulates lipolysis in adipocytes, especially in abdominal and visceral fat stores
• Reduces lipogenesis and improves mitochondrial fat oxidation

• unit: mcg

  low dose: 250

  frequency: 1–2x daily (AM fasted and/or pre-bed)

  high dose: 1000

  standard dose: 500

  administration route: Subcutaneous (SQ)

• Inject 1–2x daily for 4–8 weeks. Optional maintenance: 500 mcg daily 3x/week. Rotate injection sites to avoid irritation.

common: ["Injection site irritation","Mild hunger increase"]

warnings: ["Avoid use alongside insulin or IGF-1 therapies unless supervised","Not for pediatric or muscle-growth-focused use"]

long term: ["No adverse effects observed in short-term animal studies; long-term safety in humans unverified"]

sequence: Thr-Ser-Ile-Cys-Ser-Val-Glu-Gln-Gly-Glu-Arg-Ala-Arg-Leu-Asp-Arg-Ile-Arg-Glu-Lys-Ala-Gly-Phe-Ser

half life: Approximately 30 minutes

degradation: Metabolized in liver and blood via proteases

molecular weight: 1817.1

molecular formula: C78H125N23O23S2

tissue specificity: Targets adipose tissue with minimal systemic growth impact

• Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.mechanismPMID 11146367 ↗
• Increase of fat oxidation and weight loss in obese mice by a modified C-terminal fragment of hGH.preclinicalPMID 11673763 ↗